• INBRX-101 is built to provide greater clinical activity to pdAAT by offering sustained improved concentration of plasma within a less frequent, regimen of monthly dosing.  
   
• Inhibrx anticipates to unveil preliminary functional pharmacokinetic data collected during the single-dose phase of the study in the first six months of 2020.

Inhibrx Inc., an international biotechnology company founded in 2010 aimed at developing a pipeline of new biologic therapeutic candidates, reportedly announced the registration of first patient in its Phase 1 clinical trial of a therapeutic candidate INBRX-101 (NCT03815396).

NCT03815396 is a therapeutic candidate based on Fc-fusion protein which comprises improved recombinant iterations of human alpha-1 antitrypsin to treat alpha-1 antitrypsin deficiency, commonly called AATD, in patients.

AATD is a rare respiratory disease that is characterized by continuous impairment of lung tissue which leads to emphysema and COPD. Reports cite, approx. 100,000 people are affected by this disease across the United States with Europe numbers being at the same approximate level.

Plasma derived augmentation therapy (pdAAT), present standard of care of patients affected with AATD, has remained unchanged for several decades and depends on the weekly infusions of AAT derived from plasma purified from the human donor serum.

The company’s therapeutic candidate INBRX-101 is developed to provide greater clinical activity into pdAAT by offering sustained improved concentration of plasma within a less frequent, regimen of monthly dosing.   

CEO of Inhibrx, Mark Lappe stated that the company applied its protein engineering capabilities for overcoming the challenges associated with producing functional recombinant human alpha-1 antitrypsin, apart from identifying modifications that the company believes to be capable to optimize PK functionality and profile. Mark further added that the company is thrilled to start enrollment of Phase 1 trial to assess the potential advantages of INBRX-101 in individuals affected by AATD.

Inhibrx anticipates to unveil preliminary functional pharmacokinetic data collected during the single-dose phase of the study in the first 6 months of 2020.

Source credit: https://inhibrx.com/inhibrx-announces-enrollment-of-first-patient-in-phase-1-study-of-inbrx-101-a-modified-recombinant-human-aat-fc-fusion-protein/